Your comments on the Ambrisentan data are very interesting to me as someone who is checking out ENCY. DrBio wrote that patients with connective tissue disease were excluded form the ARIES trials. I do not see this in the protocol (ENCY's included for comaparison):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.